arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Ultragenyx Pharmaceutical Inc.

RARE Health Care Biotechnology: Pharmaceutical Preparations
$15.38
▲ +0.5% Today
as of Sep 4, 16:53 ET
Last 30 days -41.11% Jul 28 → Sep 04
$13.88 $17.39 $20.90 $24.42 $27.93 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$15.47
High
$16.08
Low
$15.24
Volume
$11M
Avg Vol
$2M
Mkt Cap
$2.6B
P/E (TTM)
—
Beta
—
52w High
$39.89
52w Low
$13.81
Div Yield
—
Shares Out
$99M

Recent Press Releases & News last 60 days · 25 items

Sep 5 · 01:08 Simply Wall St.
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan
Sep 5 · 00:18 Simply Wall St.
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback
Sep 4 · 07:24 Stocktwits
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$14
$40
6% of range
Avg surprise (last 3)
-4.3%
Avg reaction (last 2)
-4.5%
50% positive
Latest IV / EM
55%
EM ±8.7% · $15 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.33$-1.97$-1.61$-1.26$-0.90 Actual $-2.33Actual $-2.25Actual $-2.23Actual $-2.03Actual $-1.52Actual $-1.40Actual $-1.57Est $-1.54Actual $-1.17Est $-1.27Actual $-1.81Actual $-1.84Est $-1.55Actual $-0.90 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-185M$-83M$20M$122M$225M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.90 — — — — financials
Tue May 5, 2026Mar/2026 $-1.84 $-1.55 -18.7% -17.2% +0.8% earnings
Tue Sep 30, 2025Sep 2025 $-1.81 — — — — financials
Tue Aug 5, 2025Jun/2025 $-1.17 $-1.27 +7.9% — — earnings
Tue May 6, 2025Mar/2025 $-1.57 $-1.54 -1.9% — -9.8% earnings
Mon Sep 30, 2024Sep 2024 $-1.40 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.52 — — — — financials
Sun Mar 31, 2024Mar 2024 $-2.03 — — — — financials
Sat Sep 30, 2023Sep 2023 $-2.23 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.25 — — — — financials
Fri Mar 31, 2023Mar 2023 $-2.33 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$214M$136M—$160M$167M$139M—$139M
Cost of revenue————————
Gross profit————————
Operating income$-75M$-169M—$-171M$-108M$-143M—$-132M
Net income$-92M$-185M—$-180M$-115M$-151M—$-134M
EPS (diluted)$-0.90$-1.84—$-1.81$-1.17$-1.57—$-1.40

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$125M$175M$421M$203M$176M$127M$174M$151M
Inventory$59M$55M$52M$52M$46M$46M$45M$43M
Total current assets$606M$657M$951M$643M$720M$699M$817M$800M
Total assets$1.26B$1.30B$1.53B$1.19B$1.31B$1.31B$1.50B$1.54B
Long-term debt————————
Total liabilities$1.55B$1.52B$1.60B$1.17B$1.15B$1.16B$1.24B$1.18B
Total equity$-291M$-236M$-80M$9M$151M$144M$255M$347M

Implied volatility — last 90 days

51%168%284%400%517% Jun 07 — IV 71% · EM ±9.8%Jun 08 — IV 119% · EM ±15.7%Jun 09 — IV 59% · EM ±7.4%Jun 10 — IV 53% · EM ±6.2%Jun 11 — IV 94% · EM ±10.4%Jun 12 — IV 57% · EM ±5.9%Jun 15 — IV 52% · EM ±3.7%Jun 16 — IV 89% · EM ±5.2%Jun 17 — IV 125% · EM ±5.2%Jun 19 — IV 63% · EM ±13.8%Jun 22 — IV 61% · EM ±12.8%Jun 23 — IV 58% · EM ±11.8%Jun 24 — IV 55% · EM ±11.1%Jun 25 — IV 52% · EM ±10.3%Jun 26 — IV 54% · EM ±10.3%Jun 29 — IV 55% · EM ±9.7%Jun 30 — IV 58% · EM ±10.0%Jul 01 — IV 58% · EM ±9.7%Jul 02 — IV 52% · EM ±8.4%Jul 03 — IV 54% · EM ±8.4%Jul 06 — IV 86% · EM ±11.9%Jul 07 — IV 54% · EM ±7.1%Jul 08 — IV 63% · EM ±7.8%Jul 09 — IV 54% · EM ±6.3%Jul 10 — IV 64% · EM ±7.0%Jul 14 — IV 57% · EM ±4.1%Jul 15 — IV 94% · EM ±5.5%Jul 20 — IV 124% · EM ±29.4%Jul 21 — IV 132% · EM ±30.7%Jul 22 — IV 112% · EM ±25.6%Jul 23 — IV 95% · EM ±21.3%Jul 24 — IV 109% · EM ±24.2%Jul 27 — IV 120% · EM ±25.0%Jul 28 — IV 82% · EM ±16.8%Jul 29 — IV 117% · EM ±23.3%Jul 30 — IV 111% · EM ±21.8%Jul 31 — IV 105% · EM ±20.2%Aug 03 — IV 111% · EM ±19.7%Aug 04 — IV 92% · EM ±15.8%Aug 05 — IV 76% · EM ±12.6%Aug 06 — IV 59% · EM ±9.6%Aug 07 — IV 68% · EM ±10.6%Aug 10 — IV 74% · EM ±10.3%Aug 11 — IV 87% · EM ±11.5%Aug 12 — IV 60% · EM ±7.5%Aug 13 — IV 87% · EM ±10.2%Aug 14 — IV 83% · EM ±9.2%Aug 17 — IV 144% · EM ±12.1%Aug 18 — IV 89% · EM ±6.5%Aug 19 — IV 122% · EM ±7.2%Aug 24 — IV 121% · EM ±25.3%Aug 25 — IV 114% · EM ±23.4%Aug 26 — IV 108% · EM ±21.7%Aug 27 — IV 110% · EM ±21.5%Aug 28 — IV 126% · EM ±24.1%Aug 31 — IV 144% · EM ±25.6%Sep 01 — IV 140% · EM ±24.1%Sep 02 — IV 517% · EM ±86.4%Sep 03 — IV 76% · EM ±12.3%Sep 04 — IV 55% · EM ±8.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in